NEWSROOM

PRISM MarketView

PRISM MediaWire – Weekly Press Resume – Dec. 25 to Dec. 29, 2023

PRISM MediaWire – Weekly Press Resume – Dec. 25 to Dec. 29, 2023

Dec 29, 2023

New York, December 29, 2023 PRISM MediaWire - Weekly Press Resume Dec. 25 to Dec. 29, 2023 SS Innovations Announces Strategic Partnership with Surgical Lab for Distribution in Africa https://prismmediawire.com/ss-innovations-announces-strategic-partnership-with-surgical-lab-for-distribution-in-africa/ SPZI: $53.4 million fully executed commodity contract closed https://prismmediawire.com/spzi-53-4-million-fully-executed-commodity-contract-closed/ Rodedawg Intl. Ind, Inc. (OTC: RWGI) Acquires...

Most Popular PRISM MarketView Articles in 2023

Most Popular PRISM MarketView Articles in 2023

Dec 29, 2023

New York, December 29, 2023 - 2023 was a year filled with significant developments in emerging stocks, featuring a wide range of topics from clinical updates and strategic partnerships to earnings reports. Notable stories include Oncocyte’s initiation of the FDA submission process for its kidney transplant monitoring test, SKYX’s partnership with Kichler, and Soluna’s robust Q3 earnings. The year also saw engaging discussions on unique topics like full moon trading, Thanksgiving strategies,...

Microbot Medical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%

Microbot Medical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%

Dec 28, 2023

New York, December 28, 2023 - Microbot Medical Inc. (Nasdaq: MBOT) has completed its GLP pivotal pre-clinical study for the LIBERTY® Endovascular Robotic Surgical System. The study, adhering to FDA guidelines and using a porcine model, successfully met all its objectives, including conducting 96 robotic navigations by three interventional radiologists. This involved evaluating target vessels and surrounding tissues with the LIBERTY system controlling various intravascular catheterization...

Enveric Biosciences Announces EB-003 as Lead Drug Candidate for Mental Health Disorders; Stock Jumps 37%

Enveric Biosciences Announces EB-003 as Lead Drug Candidate for Mental Health Disorders; Stock Jumps 37%

Dec 28, 2023

New York, December 28, 2023 - Enveric Biosciences (NASDAQ: ENVB), a biotechnology company specializing in developing novel treatments for mental health disorders, has named EB-003 as the lead candidate from its EVM301 Series. This series targets depression, anxiety, and addiction disorders. The selection of EB-003 is a key milestone for Enveric, transitioning the company from a discovery phase to a drug development phase. EB-003 is chosen for its potential to...

SinglePoint Successfully Lists on Cboe; Welcomes Tony Thomas as New Board Member in Expansion of Board Bolstering Company’s Commitment to Strategic Growth in the Solar Sector

SinglePoint Successfully Lists on Cboe; Welcomes Tony Thomas as New Board Member in Expansion of Board Bolstering Company’s Commitment to Strategic Growth in the Solar Sector

Dec 28, 2023

Phoenix, AZ, December 28, 2023 - SinglePoint Inc. (Cboe: SING) (“SinglePoint'' or “the Company'') a provider in renewable energy, energy supply and healthy building solutions is delighted to announce the appointment of Tony Thomas to its Board of Directors. Mr. Thomas brings a wealth of experience and expertise in strategic advisory, investment, and board governance. Mr. Thomas serves as a Managing Director and Head of the financial advisory and asset management practice of Harbor...

PRISM Emerging MedDevices Mover Spotlight: Milestone Scientific Inc. (MLSS)

PRISM Emerging MedDevices Mover Spotlight: Milestone Scientific Inc. (MLSS)

Dec 27, 2023

New York, December 27, 2023 - Milestone Scientific Inc. (NYSE:MLSS) has established itself in the field of biomedical technology with its focus on advanced injection technologies for medical and dental applications. The company holds over 19 US patents and 133 foreign patents. Its dental product, the Single Tooth Anesthesia System (STA), has received FDA and CE marketing clearance in more than 50 countries. The STA system utilizes computer-assisted technology for precise and consistent...

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

Dec 27, 2023

New York, December 27, 2023 - Immutep Limited (ASX: IMM; NASDAQ: IMMP), a trailblazing clinical-stage biotechnology company, has announced encouraging news from the Paul-Ehrlich-Institut (PEI), part of the Committee for Medicinal Products for Human Use (CHMP). This announcement marks a significant step forward in the company’s development of novel LAG-3 immunotherapies for cancer and autoimmune diseases. https://prismmarketview.com/companies/immutep-limited/#news Marc Voigt, CEO of Immutep...

PRISM MediaWire – Weekly Press Resume – Dec. 25 to Dec. 29, 2023

PRISM MediaWire – Weekly Press Resume – Dec. 18 to Dec. 22, 2023

Dec 22, 2023

New York, December 22, 2023 PRISM MediaWire - Weekly Press Resume Dec. 18 to Dec. 22, 2023 SinglePoint Rings the Opening Bell at Cboe Global Markets Exchange https://prismmediawire.com/singlepoint-rings-the-opening-bell-at-cboe-global-markets-exchange/ MindMed Advances Treatment for Generalized Anxiety Disorder https://prismmediawire.com/mindmed-advances-treatment-for-generalized-anxiety-disorder/ PRISM Analysis: Why Did Battalion Oil Shares Soar on Friday?...

HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment

HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment

Dec 22, 2023

New York, December 22, 2023 - Gilead Sciences (Nasdaq: GILD) has purchased 15 million shares of immunotherapeutics company, HOOKIPA Pharma’s (Nasdaq: HOOK), common stock for approximately $21.25 million, at a price of $1.4167 per share. Under the agreement, HOOKIPA is responsible for advancing its HIV program through the completion of a Phase 1b clinical trial. The company’s shares rose 52.65% on Thursday and 80.51% premarket on Friday. https://prismmarketview.com/companies/hookipa-pharma-inc/...

PRISM Analysis: PetVivo Holdings Achieves Distribution Milestone; Shares Soar 40%

PRISM Analysis: PetVivo Holdings Achieves Distribution Milestone; Shares Soar 40%

Dec 22, 2023

New York, December 22, 2023 - PetVivo Holdings, Inc. (Nasdaq: PETV) has achieved a distribution milestone, reporting a total of 4500 syringes of Spryng™ with OsteoCushion™ technology distributed to veterinarians in the 2023 calendar year. https://prismmarketview.com/companies/petvivo-holdings-inc/ Spryng, the company’s signature product, helps to manage lameness, joint pain and osteoarthritis in horses and small animals. Earlier this month, the company announced the sale of Spryng to more...

PRISM Analysis: Why Did CareCloud Shares Jump This Week?

PRISM Analysis: Why Did CareCloud Shares Jump This Week?

Dec 22, 2023

New York, December 22, 2023 - Healthcare technology solutions provider, CareCloud, Inc. (Nasdaq: CCLD) has seen a jump in its share price this week. The new momentum is being driven by the company’s financial and operational update, issued on Wednesday, and outlining an attractive roadmap for future growth. Shareholders rewarded CareCloud with a 25.61% increase following Wednesday’s session, and a 22.94% boost on Thursday. https://prismmarketview.com/companies/carecloud-inc/ Remarking on the...

Ring In The New Year with Traditions and Trades: Cultural Celebrations and Stock Plays for a Prosperous Start

Ring In The New Year with Traditions and Trades: Cultural Celebrations and Stock Plays for a Prosperous Start

Dec 21, 2023

New York, December 21, 2023 - In two weeks, 2023 will be history so consider this your reminder to start figuring out a resolution that likely will be forgotten, by this time next year. New Years is celebrated in a multitude of ways based on geography, culture, or religion. However, unlike other holidays, it is one that is observed by mostly everyone around the world. As always, PRISM has you covered as we close out the year and provide you with some “go-to” resolution ideas, highlight some...

Palatin Technologies Sells Vyleesi in $171M Transaction

Palatin Technologies Sells Vyleesi in $171M Transaction

Dec 21, 2023

New York, December 21, 2023 - Palatin Technologies, Inc. (NYSE American: PTN) has completed the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, specialty pharmaceutical company, for up to $171 million. Vyleesi is the first and only as-needed FDA-approved treatment for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). https://prismmarketview.com/companies/palatin-technologies-inc/ Carl Spana, Ph.D., President and Chief Executive Officer of...

SinglePoint Successfully Lists on Cboe; Welcomes Tony Thomas as New Board Member in Expansion of Board Bolstering Company’s Commitment to Strategic Growth in the Solar Sector

SinglePoint CEO Releases Shareholder Letter Overviewing 2023 and Successful Listing on Cboe BZX Exchange

Dec 21, 2023

Successfully Uplisted to Cboe BZX Exchange December 15, 2023 Year to Date Revenue Crossing $30 million Completed $4,000,000 Underwritten Offering Capital Raise Phoenix, AZ, December 21, 2023 - SinglePoint Inc. (Cboe: SING) a leading renewable solar energy and sustainable solutions provider releases shareholder letter overviewing 2023 and Successful listing on Cboe BZX Exchange. Dear Shareholders, As we approach the end of a tough yet remarkable year, I am pleased to share a comprehensive...

Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial

Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial

Dec 21, 2023

New York, December 21, 2023 - Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has received FDA clearance to conduct a phase 1/2 clinical trial using the company’s innovative StemSpine® treatment known as AlloStem™ (CELZ-201-DDT). https://prismmarketview.com/companies/creative-medical-technology-holdings-inc/ Timothy Warbington, CEO of Creative Medical Technology, said, “The FDA’s clearance and IRB approval allowing us to pursue this clinical trial is another...

PRISM BIOTECH IN MOTION: FDA APPROVAL FOR PANBELA THERAPEUTICS PEDIATRIC CANCER DRUG; SHARES JUMP 120%

PRISM BIOTECH IN MOTION: FDA APPROVAL FOR PANBELA THERAPEUTICS PEDIATRIC CANCER DRUG; SHARES JUMP 120%

Dec 20, 2023

New York, December 20, 2023 - PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights Panbela Therapeutics, Inc. which has announced that US WorldMeds®1 (USWM) has received FDA approval of its New Drug Application (NDA) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients. In July 2023, Panbela divested its pediatric neuroblastoma program to USWM in an arrangement entitling Panbela to up to approximately $9.5...

PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success

PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success

Dec 20, 2023

New York, December 20, 2023 - Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is celebrating a year of strategic accomplishments on its first anniversary as a public company. Lipella is advancing three clinical indications and has been granted two Orphan Drug Designations by the US Food and Drug Administration (FDA). https://prismmarketview.com/companies/lipella-pharmaceuticals-inc/ Today, the company announced it has successfully completed a Type C meeting with...

Buy Now, Pay Later: Affirm Shares Jump on News of Walmart Partnership

Buy Now, Pay Later: Affirm Shares Jump on News of Walmart Partnership

Dec 20, 2023

New York, December 20, 2023 - Shares in payment network company, Affirm Holdings (Nasdaq: AFRM), jumped more than 15% on Tuesday after the company announced it would expand its partnership with Walmart to offer a Buy Now, Pay Later (BNPL) service at self-checkout kiosks at over 4,500 Walmart stores in the United States. https://prismmarketview.com/companies/affirm-holdings-inc/ https://prismmarketview.com/buy-now-pay-later-affirm-shares-jump-on-news-of-walmart-partnership/ Pat Suh, Affirm’s...

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

Dec 20, 2023

-Lipella Granted Two Orphan Drug Designations by FDA- Pittsburgh, PA, December 20, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company") a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the Company has made substantial strides over the past year, achieving critical milestones and advancing its pipeline with three clinical indications and two orphan drug designations...

SinglePoint Announces Closing of $4 Million Public Offering, Uplisting to Cboe Global Markets and Reverse Stock Split

SinglePoint Announces Closing of $4 Million Public Offering, Uplisting to Cboe Global Markets and Reverse Stock Split

Dec 19, 2023

Phoenix, AZ, December 19, 2023 - SinglePoint Inc. (Cboe: SING) (“SinglePoint” or the “Company”), a diversified holding company principally engaged through its subsidiaries in providing renewable energy solutions and energy-efficient applications to drive better health and living, today announced the closing of its underwritten public offering of 800,000 shares of common stock at a public offering price of $5.00 per share. The gross proceeds from the offering, before underwriting discounts...

NRx Pharmaceuticals Secures IND for Urinary Tract Infection Treatment

NRx Pharmaceuticals Secures IND for Urinary Tract Infection Treatment

Dec 19, 2023

New York, December 19, 2023 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has been granted FDA clearance for its Investigational New Drug Application (IND) for NRX-101 for the treatment of complicated Urinary Tract infections (cUTI). The company’s shares surged 25% in trading on Monday following the news. https://prismmarketview.com/companies/nrx-pharmaceuticals-inc/ Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have...

PPJ Healthcare Enterprises, Inc. signed new Billing Accounts

PPJ Healthcare Enterprises, Inc. signed new Billing Accounts

Dec 19, 2023

TAMPA, FLORIDA, December 19, 2023 - PPJ Healthcare Enterprises Inc. (OTC Pink: PPJE) has announced today that it closed one billing agreement with a ‘pain management physicians’ group to provide their billing and collections. “We have been successful in providing specialty billing services for over 33 years, and we are very excited to add this group of physicians. The initial term of this agreement is two years. After taking time to sort out issues that held us back, the Company will now...

BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors

BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors

Dec 19, 2023

POMPANO BEACH, FLORIDA, December 19, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announces it has appointed Mr. Patrick Daly to its Board of Directors. Mr. Daly is an award-winning executive leader with a strong track record of success in operations, strategy, sales, marketing, fundraising, and partnership-building. BioStem...

PRISM Analysis: Why Did Battalion Oil Shares Soar on Friday?

PRISM Analysis: Why Did Battalion Oil Shares Soar on Friday?

Dec 18, 2023

NEW YORK, NY, December 18, 2023 - Shares in Battalion Oil Corporation (NYSE American: BATL) surged more than 80% on Friday after the company announced it has agreed to be acquired by Fury Resources, Inc. for $9.80 per share in cash, which represents a total transaction value of approximately $450 million. The transaction is expected to close in the first quarter of 2024. https://prismmarketview.com/companies/trio-petroleum-corp/ Battalion’s CEO, Matt Steele, commented, “It has been a pleasure...

MindMed Advances Treatment for Generalized Anxiety Disorder

MindMed Advances Treatment for Generalized Anxiety Disorder

Dec 18, 2023

NEW YORK, NY, December 18, 2023 - Biopharmaceutical company, Mind Medicine (Nasdaq: MNMD) has announced positive results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). The trial met its primary endpoint, with MM-120 demonstrating statistically significant and clinically meaningful dose-dependent improvements. https://prismmarketview.com/companies/mind-medicine-mindmed-inc/ Robert Barrow, Chief Executive Officer and Director of MindMed,...

SinglePoint Rings the Opening Bell at Cboe Global Markets Exchange

SinglePoint Rings the Opening Bell at Cboe Global Markets Exchange

Dec 18, 2023

Phoenix, AZ, December 18, 2023 - SinglePoint Inc. (Cboe: SING) (“SinglePoint” or the “Company”), a renewable solar energy and sustainable solutions provider participated in the iconic opening bell ringing ceremony, Friday December 15th, 2023. The event marked the successful listing of the Company’s common stock on the Cboe BZX Exchange. “It was a pleasure to initiate the Cboe opening bell in celebration of our listing,” said Ralston CEO SinglePoint Inc. “This marks a new era for...

PRISM AdTech & Media Company Spotlight: Creative Realities Illuminates the Future of Experiential Design

PRISM AdTech & Media Company Spotlight: Creative Realities Illuminates the Future of Experiential Design

Dec 16, 2023

In the fast-paced landscape of experiential design and technology, Creative Realities Inc. seamlessly integrates the physical and digital realms in creating immersive experiences that captivate audiences across various industries. NEW YORK, NY, December 16, 2023 - Creative Realities specializes in interactive displays, immersive retail solutions, and cutting-edge content creation to reshape how individuals connect with brands and spaces. With a commitment to innovation and a client-centric...

Rogue One Provides Corporate Update

Rogue One Provides Corporate Update

Dec 15, 2023

WASHINGTON, DC, December 15, 2023 -As many are aware, Rogue One, Inc. ("Company") has not submitted any financial statements subsequent to the Quarterly Report dated September 30, 2021. It is imperative to note that the recent action undertaken by the Securities and Exchange Commission on December 5, 2023, was not involuntary, but a result of a negotiated ‘Stipulation Letter' with the SEC which leads to revoking our 12G securities registration status. Consequently, Rogue One, Inc is no longer...

PRISM MediaWire – Weekly Press Resume – Dec. 11 to Dec. 15, 2023

PRISM MediaWire – Weekly Press Resume – Dec. 11 to Dec. 15, 2023

Dec 15, 2023

New York, December 15, 2023 PRISM MediaWire - Weekly Press Resume Dec. 11 to Dec. 15, 2023 UAT Group Receives Financing for Iron Removal System https://prismmediawire.com/uat-group-receives-financing-for-iron-removal-system/ SKYX and GE Sign a Five-Year Renewal of a Global Licensing Master Service Agreement as SKYX Continues to Enhance its Market Penetration and Collaborations with U.S. and World Leading Strategic Companies...

“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial

“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial

Dec 15, 2023

NEW YORK, NY, December 15, 2023 - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company’s lead drug candidate for amyotrophic lateral sclerosis (ALS). The company’s share price rose nearly 30% in trading on Thursday. https://prismmarketview.com/companies/neurosense-therapeutics-ltd/ Alon Ben-Noon, NeuroSense’s CEO, commented, “As we analyze the PARADIGM trial results, we continue to gain a better...